[1]丁皓月,王毓佳综述,泥艳红审校.肌腱蛋白在肿瘤中作用的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2019,21(02):167-170.[doi:10.3969/j.issn.1672-271X.2019.02.012]
　DING Hao-yue,WANG Yu-jia reviewing,NI Yan-hong checking.Research progress in the role of TNC in tumor[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2019,21(02):167-170.[doi:10.3969/j.issn.1672-271X.2019.02.012]

点击复制

肌腱蛋白在肿瘤中作用的研究进展()

分享到62.8K

参考文献/References:

[1] Bourdon MA, Wikstrand CJ, Furthmayr H ,et al. Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody[J]. Cancer Res, 1983, 43(6): 2796-2805.
[2] 农云宏，白浪. Tenascin-C促进肿瘤转移的分子机制研究进展[J].生物医学工程学杂志，2015，32（1）：240-244.
[3] Midwood KS, Orend G. The role of tenascin-C in tissue injury and tumorigenesis[J]. J Cell Commun Signal, 2009, 3(3-4): 287-310.
[4] Yoshida T, Akatsuka T, Imanaka-Yoshida K. Tenascin-C and integrins in cancer[J]. Cell Adh Migr, 2015, 9(1-2): 96-104.
[5] Wiese S, Faissner A. The role of extracellular matrix in spinal cord development[J]. Exp Neurol, 2015, 274(Pt B): 90-99.
[6] Fluck M, Tunc-Civelek V, Chiquet M. Rapid and reciprocal regulation of tenascin-C and tenascin-Y expression by loading of skeletal muscle[J]. J Cell Sci, 2000, 113(Pt 20)：3583-3591.
[7] Mori M, Muramatsu Y, Yamada K ,et al. Intracellular localization of tenascin in squamous cell carcinoma of oral cavity: an immunohistochemical study[J]. Anticancer Res, 1996, 16(5B): 3075-3079.
[8] Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts[J]. Cancer Res, 1989, 49(15): 4322-4325.
[9] Adams M, Jones JL, Walker RA ,et al. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease[J]. Cancer Res, 2002, 62(11): 3289-3297.
[10] Hancox RA, Allen MD, Holliday DL ,et al. Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms[J]. Breast Cancer Res, 2009, 11(2): R24.
[11] Pedretti M, Soltermann A, Arni S ,et al. Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer[J]. Lung cancer, 2009, 64(1): 28-33.
[12] Ishiwata T, Takahashi K, Shimanuki Y ,et al. Serum tenascin-C as a potential predictive marker of angiogenesis in non-small cell lung cancer[J]. Anticancer Res, 2005, 25(1B): 489-495.
[13] Xia S, Lal B, Tung B ,et al. Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation[J]. Neuro Oncol, 2016, 18(4): 507-517.
[14] Mackie EJ, Chiquet-Ehrismann R, Pearson CA ,et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland[J]. Proc Natl Acad Sci USA, 1987, 84(13): 4621-4625.
[15] Jahkola T, Toivonen T, von Smitten K ,et al. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis[J]. Int J Cancer, 1996, 69(6): 445-447.
[16] Yang ZT, Yeo SY, Yin YX ,et al. Tenascin-C, a Prognostic Determinant of Esophageal Squamous Cell Carcinoma[J]. PLoS One, 2016, 11(1): e0145807.
[17] Ni WD, Yang ZT, Cui CA ,et al. Tenascin-C is a potential cancer-associated fibroblasts marker and predicts poor prognosis in prostate cancer[J]. Biochem Biophys Res Commun, 2017, 486(3): 607-612.
[18] Gecks T, Junker K, Franz M ,et al. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?[J]. Clin Chim Acta, 2011, 412(21-22): 1931-1936.
[19] 左衍海，施鑫. 恶性肿瘤转移机制研究新进展[J]. 医学研究生学报，2008，21(3) : 293-297.
[20] Huang W, Chiquet-Ehrismann R, Moyano JV ,et al. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation[J]. Cancer Res, 2001, 61(23): 8586-8594.
[21] Fischer D, Tucker RP, Chiquet-Ehrismann R,et al. Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes[J]. Mol Biol Cell, 1997, 8(10): 2055-2075.
[22] Katoh D, Nagaharu K, Shimojo N ,et al. Binding of alphavbeta1 and alphavbeta6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells[J]. Oncogenesis, 2013, 2(8)：e65.
[23] Tanaka K, Hiraiwa N, Hashimoto H,et al. Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression[J]. Int J Cancer, 2004, 108(1): 31-40.
[24] Kawakatsu H, Shiurba R, Obara M ,et al. Human carcinoma cells synthesize and secrete tenascin in vitro[J]. Jpn J Cancer Res, 1992,83(10):1073-1080.
[25] Fukunaga-Kalabis M, Martinez G, Nguyen TK ,et al. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population[J]. Oncogene, 2010, 29(46): 6115-6124.
[26] Van Obberghen-Schilling E, Tucker RP, Saupe F ,et al. Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth[J]. Int J Dev Biol, 2011, 55(4-5): 511-525.
[27] Saupe F, Schwenzer A, Jia Y ,et al. Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model[J]. Cell Rep, 2013, 5(2): 482-492.
[28] Puente Navazo MD, Valmori D, Ruegg C. The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production[J]. J Immunol, 2001, 167(11): 6431-6440.
[29] Parekh K, Ramachandran S, Cooper J ,et al. Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes[J]. Lung cancer, 2005, 47(1): 17-29.
[30] Hauzenberger D, Olivier P, Gundersen D ,et al. Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin[J]. Eur J Immunol, 1999, 29(5): 1435-1447.
[31] Gong XG, Lv YF, Li XQ ,et al. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells[J]. Biol Pharm Bull, 2010, 33(8): 1261-1267.
[32] 黄迎娣，崔蕾，黄利鸣，等. 上皮间质转化与肿瘤耐药[J]. 东南国防医药，2014，16(6): 624-628.
[33] 胡翰青，刘蔚，马行健，等. P53蛋白、VEGF和CD34在涎腺腺样囊性癌中的表达及意义[J]. 东南国防医药，2013，15(6): 592-593.

相似文献/References: